Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer

被引：3
|
作者：
Teitelbaum, Ursina R. [1 ]
Haller, Daniel G. [1 ]
机构：
[1] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 05期
关键词：
CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED PHASE-III; THERAPY;
D O I：
10.1038/nrclinonc.2009.46
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. this paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.
引用
收藏
页码：250 / 251
页数：3
相关论文
共 50 条
  • [21] Second-line systemic therapy for metastatic colorectal cancer
    Mocellin, Simone
    Baretta, Zora
    Roque i Figuls, Marta
    Sola, Ivan
    Martin-Richard, Marta
    Hallum, Sara
    Cosp, Xavier Bonfill
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (01):
  • [22] Second-line treatment of patients with metastatic colorectal cancer
    Rougier, P
    Lepere, C
    SEMINARS IN ONCOLOGY, 2005, 32 (06) : S48 - S54
  • [23] Irinotecan in second-line therapy of metastatic colorectal cancer
    Jäger, E
    Jäger, D
    Orth, J
    Knuth, A
    ONKOLOGIE, 2000, 23 : S15 - S17
  • [24] IROX as second-line therapy for metastatic colorectal cancer
    Sobrero, Alberto
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 248 - 250
  • [25] Folfox-4 regimen in a single center unselected series of metastatic colorectal cancer patients
    Rampinelli, I
    Bucci, E
    Di Lucca, G
    Scaglietti, U
    Cererani, N
    Guffanti, M
    Zerini, D
    Verasio, C
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [26] A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin
    He, Shengli
    Shen, Jie
    Sun, Xianjun
    Liu, Luming
    Dong, Jingcheng
    JOURNAL OF CHEMOTHERAPY, 2014, 26 (04) : 243 - 247
  • [27] FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients
    Dodagoudar, Chandragouda
    Doval, Dinesh Chandra
    Mahanta, Anupam
    Goel, Varun
    Upadhyay, Amitabh
    Goyal, Pankaj
    Talwar, Vineet
    Singh, Sajjan
    John, Mithun Chacko
    Tiwari, Srikant
    Patnaik, Nivedita
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (01) : 57 - 62
  • [28] FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer
    Petrioli, Roberto
    Paolelli, Loretta
    Marsili, Stefania
    Civitelli, Serenella
    Francini, Edoardo
    Cioppa, Tommaso
    Roviello, Franco
    Nettuno, Raffaele
    Intrivici, Chiara
    Tanzini, Gabriello
    Lorenzi, Marco
    Francini, Guido
    ONCOLOGY, 2006, 70 (05) : 345 - 350
  • [29] FOLFOX-4 versus FOLFIRI in the treatment of metastatic colorectal cancer - a prospective randomised study
    Badulescu, F.
    Badulescu, A.
    Schenker, M.
    Ionescu, M.
    Ninulescu, C.
    Crisan, A.
    Dinescu, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 349 - 349
  • [30] First- and second-line therapy of metastatic colorectal cancer
    Terstriep, Shelby
    Grothey, Axel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (06) : 921 - 930
12345